Cybin Secures New U.S. Patent for CYB003 Program in Major Depressive Disorder

Cybin ( (TSE:CYBN) ) has provided an update.

Cybin has announced the granting of a new U.S. patent for its CYB003 program, which is in Phase 3 development for major depressive disorder. This patent, providing exclusivity until 2041, strengthens Cybin’s intellectual property portfolio, which includes over 80 granted patents and 230 pending applications. The announcement underscores Cybin’s commitment to advancing its pipeline and delivering shareholder value, as it continues patient dosing in its first Phase 3 study and prepares for a second study in 2025.

Spark’s Take on TSE:CYBN Stock

According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.

Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.

To see Spark’s full report on TSE:CYBN stock, click here.

More about Cybin

Cybin is a late-stage breakthrough neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is engaged in developing proprietary programs like CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, with operations in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.

Technical Sentiment Signal: Hold

Current Market Cap: C$1.97M

Learn more about CYBN stock on TipRanks’ Stock Analysis page.